Antik?rpertherapie bei malignem Lymphom

The availability of monoclonal antibodies has revolutionized the therapy of malignant lymphoma. By adding rituximab to the therapeutic arsenal, response rates, progression-free survival and even overall survival could be improved for several lymphoma entities. Ritxuimab is used as part of induction and maintenance therapy as well as in the relapse situation for follicular lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma and chronic lymphocytic leukemia (CLL). The successors, ofatumumab and obinutuzumab are currently being tested in clinical trials. Other antibodies target CD22, CD52 and CD80. The CD52 targeting antibody alemtuzumab is approved for fludarabine refractory CLL by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and is also effective in patients with high risk cytogenetics. Apart from conventional antibodies, the bispecific T-cell engager (BiTE) single-chain variable fragments (scFv) antibody blinatumomab is currently being tested in clinical trials. This review gives an overview of antibody therapy for malignant lymphoma.